MDLive Review

MDLive: GLP-1s tucked inside real primary care, not a weight-loss funnel

MDLive is not a dedicated weight-loss startup. It is a large, established telehealth service owned by Evernorth, the health-services arm of Cigna, and it reaches more than 50 million people through insurance and employer benefits. Weight management is just one corner of a platform that also handles urgent care, primary care, dermatology and behavioral health. That matters because it shapes everything about how you actually get a GLP-1 here: there is no slick "start your weight-loss journey" checkout, no monthly subscription box, and no compounded knock-off. You see a board-certified primary care physician, and an anti-obesity medication may be prescribed if that doctor judges it appropriate.

How a GLP-1 prescription actually happens here

This is the single most important thing to understand before you sign up. MDLive only prescribes anti-obesity GLP-1s during a Primary Care routine visit, not during an urgent-care visit, and only at the clinician's discretion. There is no guarantee of a script. You are booking a genuine medical appointment with a physician who will look at your history and decide, rather than filling out an intake form engineered to approve nearly everyone. For patients who want real oversight that is a feature. For anyone expecting a near-automatic yes, it is a hurdle.

The medications on the table are all FDA-approved branded drugs the provider has confirmed it can prescribe at a doctor's discretion:

• Wegovy (branded semaglutide)
• Zepbound (branded tirzepatide)
• Saxenda (a daily injectable)
• Contrave (an oral, non-GLP-1 weight option)

Notice what is absent: there is no compounded semaglutide or tirzepatide, and no in-house pharmacy markup. MDLive writes the prescription and you fill the branded drug at a pharmacy, which means coverage and your plan's formulary do most of the work in determining what you actually pay.

Why there is no headline monthly price

MDLive does not publish a flat cash price for GLP-1 care, and that is by design rather than an oversight. Because the service is distributed mainly through insurers and employer plans, your cost is whatever your benefits dictate: a visit copay plus whatever your plan charges for the branded drug. Out-of-pocket direct visits are allowed too, but even then you are paying a visit fee and then the pharmacy's price for branded Wegovy or Zepbound, which carries a high four-figure list price before any coverage.

So the honest framing is this: if your insurance or employer covers anti-obesity medication, MDLive can be one of the cheapest legitimate routes to a branded GLP-1, potentially a modest copay rather than the category median of around $170 that cash-pay compounding services charge. If you have no coverage for these drugs, MDLive is likely the wrong tool, because you would be paying full branded list price with none of the cash-pay discounts a dedicated compounding provider builds its whole model around.

The state exclusions you have to check first

Anti-obesity medications are explicitly unavailable through MDLive in Florida, Louisiana, Mississippi and New Jersey. This is confirmed directly from MDLive's own materials, not an assumption. If you live in one of those four states, you can still use MDLive for primary or urgent care, but you cannot get a weight-loss GLP-1 here, full stop. Confirm your state before you spend anything.

Trust and medical oversight

On the credibility front MDLive is among the strongest names in this category. Its clinicians are board-certified physicians averaging roughly 15 years of experience, and the whole operation sits inside Evernorth/Cigna, a major healthcare organization rather than a venture-backed pop-up. There are no FDA warnings on file for MDLive in our records, and because it dispenses only branded, FDA-approved medications, you sidestep the quality-control questions that surround some compounded-peptide sellers entirely. For a discretion-based model like this, that institutional weight is reassuring. You can see how we weigh these factors in our scoring methodology.

Who should choose MDLive, and who should skip it

Choose MDLive if you have insurance or employer benefits that cover anti-obesity drugs, you want a branded GLP-1 instead of a compounded version, and you value seeing an experienced physician who manages your overall health rather than just refilling a pen. It is also a sensible pick if you already use MDLive for other care and want continuity.

Skip it if you are paying entirely out of pocket and chasing the lowest possible monthly cost, if you want a guaranteed prescription from a quick intake, or if you live in Florida, Louisiana, Mississippi or New Jersey. Cash-pay shoppers will almost always do better, on price and on price transparency, with a dedicated GLP-1 service that publishes a flat monthly rate.

Bottom line

MDLive is a legitimate, well-established way to get branded Wegovy or Zepbound through real primary care, and for insured or employer-covered patients it can be both cheaper and better-supervised than a standalone weight-loss site. The trade-offs are equally real: prescriptions are never guaranteed, there is no published cash price, four states are excluded, and uninsured patients get little of the value. Treat MDLive as an insurance-first option, confirm your coverage and your state, and it can be one of the safer, more clinically grounded choices on this list.

For a side-by-side, Sesame Care ($59/month) and bmiMD ($99/month) are the most comparable options to weigh against MDLive.